Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria
An open label, multicenter roll-over extension program (REP) to characterize the long-term safety and tolerability of iptacopan (LNP023) in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) who have completed PNH Phase 2 and Phase 3 studies with iptacopan. An open label, multicenter roll-over extension program (REP) to characterize the long-term safety an ...
Paroxysmal Nocturnal Hemoglobinuria
Taken orally b.i.d. Dosage supplied: 200 mg Dosage form: hard gelatin capsule Route of administration: oral Taken orally b.i.d. Dosage supplied: 200 mg Dosage form: hard gelatincapsule Route of administration ...